Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2021, Vol. 26 ›› Issue (1): 88-97.doi: 10.12092/j.issn.1009-2501.2021.01.012

Previous Articles     Next Articles

Research advances of histone deacetylase 3 in cardiovascular diseases

CHEN Lifang, WANG Bo, WANG Weirong   

  1. School of Basic Medical Science, Xi'an Jiaotong University Health Science Center, Xi'an 710061, Shanxi, China
  • Received:2020-07-09 Revised:2020-11-28 Online:2021-01-26 Published:2021-02-01

Abstract: Histone deacetylases (HDACs) are a class of epigenetic modification enzymes and closely related to chromatin structure and gene transcriptional regulation. HDAC3 belongs to class I HDACs. It is reported that HDAC3 plays a key role in heart development. Recent studies find that HDAC3 plays an important regulatory role in cardiovascular diseases. This paper reviews the class I HDAC family HDAC3, focuses on its localization, enzyme activity and the research progress of HDAC3 in congenital heart disease, coronary atherosclerotic heart disease, cardiomyopathies, heart failure, and arrhythmias. This review may provide new drug target for the clinical treatment of cardiovascular diseases.

Key words: HDAC3, acetylation modification, congenital heart disease, coronary atherosclerotic heart disease, cardiomyopathies, heart failure, arrhythmias

CLC Number: